---
layout: default
title: Vismodegib
description: "Vismodegib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 192
evidence_level: L2
indication_count: 10
---

# Vismodegib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Vismodegibï¼šå¾åŸºåº•ç´°èƒç™Œåˆ°è‘—è‰²æ€§ä¹¾çš®ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Vismodegib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Vismodegib åŸæœ¬ç”¨æ–¼æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è‘—è‰²æ€§ä¹¾çš®ç—‡ (Xeroderma Pigmentosum)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **5 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ã€‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | basal cell carcinomaã€medulloblastoma with extensive nodularityã€sebaceous adenocarcinomaã€sweat gland cancerã€xeroderma pigmentosumã€skin carcinomaã€annular epidermolytic ichthyosisã€epidermolysis bullosa simplex with mottled pigmentationã€prostate cancer/brain cancer susceptibilityã€Brenner tumor |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.91% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Research Question |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. medulloblastoma with extensive nodularity</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒVismodegib æ˜¯ Hedgehog ä¿¡è™Ÿé€šè·¯æŠ‘åˆ¶åŠ‘ï¼Œ</p>
<p>å…¶æˆåˆ†åœ¨åŸºåº•ç´°èƒç™Œä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼è‘—è‰²æ€§ä¹¾çš®ç—‡æ‚£è€…çš„åŸºåº•ç´°èƒç™Œã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/36921168/">36921168</a></td>
<td>2023</td>
<td>Case report</td>
<td>Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo</td>
<td>æœ¬ç ”ç©¶æ—¨åœ¨æè¿°è‘—è‰²æ€§ä¹¾çš®ç—‡ï¼ˆXPï¼‰çš„ç–¾ç—…å’Œæ²»ç™‚ï¼Œä¸¦æé†’é†«ç™‚å°ˆæ¥­äººå“¡åŠæ—©è­˜åˆ¥æ‚£è€…çš„ç—‡ç‹€å’Œå¾µå…†ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/35283513/">35283513</a></td>
<td>2021</td>
<td>Review</td>
<td>Indian journal of dermatology</td>
<td>æœ¬æ–‡æ¢è¨äº† XP çš„æ²»ç™‚ç­–ç•¥ï¼ŒåŒ…æ‹¬é¿å…é™½å…‰ã€æ‰‹è¡“åˆ‡é™¤ç™Œæ€§ç—…è®Šã€æ¿€å…‰å’Œå…‰å‹•åŠ›ç™‚æ³•ï¼Œä»¥åŠä½¿ç”¨ç¶­ç”²é…¸ã€5-FUã€å’ªå–¹è«å¾·ç­‰ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28297142/">28297142</a></td>
<td>2017</td>
<td>Case report</td>
<td>Pediatric dermatology</td>
<td>å ±å°äº†ä¸€å 8 æ­² XP æ‚£è€…ä½¿ç”¨ Vismodegib æ²»ç™‚é¼»å°–çš„çµç¯€æ€§åŸºåº•ç´°èƒç™Œï¼Œ4 å€‹æœˆå¾Œç—…è®Šæ¶ˆé€€ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30178564/">30178564</a></td>
<td>2018</td>
<td>Case report</td>
<td>Pediatric dermatology</td>
<td>ä¸€å XP æ‚£è€…ä½¿ç”¨ Vismodegib æ²»ç™‚å¤šå€‹åŸºåº•ç´°èƒç™Œï¼Œæ²»ç™‚ 16.5 å€‹æœˆå¾Œç—…è®Šç›´å¾‘æ¸›å°‘ 61%ã€‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/33901791/">33901791</a></td>
<td>2021</td>
<td>Case report</td>
<td>European journal of cancer (Oxford, England : 1990)</td>
<td>ç ”ç©¶äº†ä¸€å XP æ‚£è€…ä½¿ç”¨é¶å‘æ²»ç™‚å’Œå…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘æ²»ç™‚ä¾µè¥²æ€§è¡€ç®¡è‚‰ç˜¤å’Œä¸å¯åˆ‡é™¤çš„å¾©ç™¼æ€§åŸºåº•ç´°èƒç™Œã€‚</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. xeroderma pigmentosum</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ5 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36921168/" target="_blank">36921168</a></td><td>2023</td><td>Article</td><td>Revista paulista de </td><td>Xeroderma pigmentosum: case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35283513/" target="_blank">35283513</a></td><td>2021</td><td>Article</td><td>Indian journal of de</td><td>Current Therapeutic Strategies of Xeroderma Pigmentosum.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28297142/" target="_blank">28297142</a></td><td>2017</td><td>Article</td><td>Pediatric dermatolog</td><td>Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30178564/" target="_blank">30178564</a></td><td>2018</td><td>Article</td><td>Pediatric dermatolog</td><td>Use of vismodegib for the treatment of multiple basal cell c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33901791/" target="_blank">33901791</a></td><td>2021</td><td>Article</td><td>European journal of </td><td>Combination of targeted therapy and immune checkpoint blocke...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. annular epidermolytic ichthyosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. epidermolysis bullosa simplex with mottled pigmentation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. prostate cancer/brain cancer susceptibility</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. Brenner tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cutaneous adenocystic carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. prostate leiomyoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. skin cancer</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ23 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03035188" target="_blank">NCT03035188</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patient...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01815840" target="_blank">NCT01815840</a></td><td>PHASE2</td><td>COMPLETED</td><td>229</td><td>A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02690948" target="_blank">NCT02690948</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>16</td><td>A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03878524" target="_blank">NCT03878524</a></td><td>PHASE1</td><td>TERMINATED</td><td>2</td><td>Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART)...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01108094" target="_blank">NCT01108094</a></td><td>PHASE2</td><td>COMPLETED</td><td>29</td><td>Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 18 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37604067/" target="_blank">37604067</a></td><td>2023</td><td>Article</td><td>European journal of </td><td>European consensus-based interdisciplinary guideline for dia...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22670903/" target="_blank">22670903</a></td><td>2012</td><td>Article</td><td>The New England jour</td><td>Efficacy and safety of vismodegib in advanced basal-cell car...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31990414/" target="_blank">31990414</a></td><td>2020</td><td>Article</td><td>Journal of the Europ</td><td>Sonidegib and vismodegib in the treatment of patients with l...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26950094/" target="_blank">26950094</a></td><td>2016</td><td>Article</td><td>Nature genetics</td><td>Genomic analysis identifies new drivers and progression path...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27436804/" target="_blank">27436804</a></td><td>2016</td><td>Article</td><td>Actas dermo-sifiliog</td><td>Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatme...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. benign neoplasm of sweat gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ | æ„›ç¶­å¾·è† å›Š150æ¯«å…‹ | è† å›ŠåŠ‘ | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ã€‚ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šClarithromycinï¼ˆä¸­åº¦ï¼‰ã€Famotidineã€Ranitidineã€Rabeprazoleã€Cimetidine ç­‰ï¼ˆè¼•åº¦ï¼‰ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCYP3A4 ä»£è¬è—¥ç‰©ï¼Œè‘¡è„æŸšå¯èƒ½å½±éŸ¿è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šé¿å…è‘¡è„æŸš


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Musculoskeletal Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šMusculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit ...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šResearch Question**

**ç†ç”±ï¼š**
ç›®å‰æœ‰ä¸€äº›æ–‡ç»æ”¯æŒ Vismodegib åœ¨è‘—è‰²æ€§ä¹¾çš®ç—‡æ‚£è€…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œä½†ç¼ºä¹è‡¨åºŠè©¦é©—çš„ç›´æ¥è­‰æ“šã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†è©•ä¼°å…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§
- è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™ï¼ˆMOAï¼‰

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cisatracurium]({{ "/drugs/cisatracurium/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Ropinirole]({{ "/drugs/ropinirole/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Tetryzoline]({{ "/drugs/tetryzoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Acebutolol]({{ "/drugs/acebutolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Ritonavir]({{ "/drugs/ritonavir/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Vismodegibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/vismodegib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_vismodegib,
  title = {Vismodegibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vismodegib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
